Diligence memo · auto-generated · as of July 2, 2026
64x Bio
64x Bio: limited disclosed financing to assess.
Diligence furtherNo decisive signal either way from the public record alone — the call needs primary diligence beyond the filings.
Businessfiled
64x Bio operates in Biotech / Pharma, based in San Francisco, CA, USA. Enabling next generation medicines. A comprehensive platform and…
Sub-sector tags: Gene Therapy, Machine Learning.
Capital & rounds (filed)filed
64x Bio has raised — in disclosed capital across 0 recorded rounds, aggregated from public filings.
Valuation (modeled)modeled
No modeled valuation — too little disclosed financing to estimate one.
Financing rhythm & timingmixed
Not enough dated financing history to read a financing rhythm.
Comparablesmixed
Capital scale ranks ahead of 5% of Biotech / Pharma peers (227 compared).
Modeled value ranks above 5% of those peers.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.